Formulation & Evaluation of Eye Care Solution of Vasoconstrictor and Antihistaminic Drug for Conjuctivitis

M. B. Vyas B. Vyas
M. B. Vyas B. Vyas * §
Contact
§ Sardar Patel University

Send Message

To: Author

Formulation & Evaluation of Eye Care Solution of Vasoconstrictor and Antihistaminic Drug for Conjuctivitis

Article Fingerprint

ReserarchID

MR155N6

Formulation & Evaluation of Eye Care Solution of Vasoconstrictor and Antihistaminic Drug for Conjuctivitis Banner

AI TAKEAWAY

Connecting with the Eternal Ground
Access Review Comments
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu
Font Type
Font Size
Font Size
Bedground

Abstract

The purpose of present research work was to formulate and evaluate eye care solution of Naphazoline hydrochloride (Vasoconstrictor) and Pheniramine maleate (Antihistaminic) drug for allergic conjunctivitis. The optimum values of responses for viscous eye care solution formulation was found to be 97.6 cps viscosity, 1759 cps mucoadhesion index and 96.67 % CDR for naphazoline hydrochloride and 93.34% CDR for pheniramine maleate. These could be obtained at lower levels of NaCMC and higher level of HPMCE4M (0.25/0.6%w/w respectively).These viscous eye care solution showed acceptable physicochemical properties. The optimized formulation was found to be stable in one month study and providing prolonged release of the drug over an 8 hr period. Irritation study on rabbit eye revealed that it was non-irritant. All the rabbits’ eyes were normal by the end of 5 hour without any redness. There were no other adverse affects on the eyes throughout 8 hours study. This proves that optimized formulations of viscous eye care solution were very effective against common allergic conditions.

References

59 Cites in Article
  1. Mihai Bisca (1997). Current therapy of allergic conjunctivitis.
  2. Y Ali,K Lehmussaari (2006). Industrial perspective in ocular drug delivery.
  3. Rathore (2010). An overview and advancement in ocular drug delivery systems.
  4. M Eva,Atourtti Del Amo (2008). Current and future ophthalmic drug delivery systems, A Shift to the posterior segment.
  5. D Maurice,S Mishima (1984). Ocular Pharmacokinetics.
  6. Ripal Gaudana,J Jwala,Sai Boddu,Ashim Mitra (2009). Recent Perspectives in Ocular Drug Delivery.
  7. Maria Moya-Ortega (2013). Dexamethasone eye drops containing alpha cyclodextrin-based nanogels.
  8. M Ansari,Kohli (2008). Microemulsion as potential drug delivery system.
  9. M Kassem,A Abdelrahman (2007). Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
  10. Rania Hathout,Samar Mansour,Nahed Mortada,Ahmed Guinedi (2007). Liposomes as an ocular delivery system for acetazolamide: In vitro and in vivo studies.
  11. Th. Vandamme,L Brobeck (2007). Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide.
  12. Indu Kaur,Alka Garg,Anil Singla,Deepika Aggarwal (2010). Vesicular systems in ocular drug delivery: an overview.
  13. Jean-Louis Bourges,Sandrine Gautier,Florence Delie,Riad Bejjani,Jean-Claude Jeanny,Robert Gurny,David Benezra,Francine Behar-Cohen (2003). Ocular Drug Delivery Targeting the Retina and Retinal Pigment Epithelium Using Polylactide Nanoparticles.
  14. J Bourges,F Behar-Cohen (2006). Intraocular implants for extended drug delivery: therapeutic applications.
  15. H Sigurdsson,E Stefansson (2007). Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye.
  16. Derya Gulsen,Anuj Chauhan (2004). Ophthalmic Drug Delivery through Contact Lenses.
  17. Hitesh Sharma (2013). A novel approach sustained ocular drug delivery: In-situ Gel.
  18. Mark Babizhayev (2009). Current Ocular Drug Delivery Challenges for N-acetylcarnosine: Novel Patented Routes and Modes of Delivery, Design for Enhancement of Therapeutic Activity and Drug Delivery Relationships.
  19. T Parkinson,M Mundasad (2003). Tolerance of ocular iontophoresis in healthy volunteers.
  20. K Joossand,N Chirmule (2003). Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.
  21. K Rathore,R Nima (2009). An insight into ophthalmic drug delivery system.
  22. The Handbook of Ocular Disease Management.
  23. Santa Mark,B (2008). United States Pharmacopeia and National Formulary (USP-NF).
  24. (2917). United States Pharmacopeia and National Formulary (USP-NF).
  25. Annickludwig (2005). The use of mucoadhesive polymers in ocular drug delivery.
  26. Van Santvliet,A Ludwig (1999). Influence of the physico-chemical properties of ophthalmic viscolysers on the weight of drops dispensed from a flexible dropper bottle.
  27. Soumendra Sahoo,Al (2010). Mucoadhesive nanopolymer -a novel drug carrier for topical ocular drug delivery.
  28. C Raymond,Siân C Rowa,Owen (2006). Handbook of Pharmaceutical Excipients.
  29. Sahoo Soumendra (2010). Tamarind seed polysaccharide: a versatile biopolymer for mucoadhesive applications.
  30. C Raymond,Siân C Rowa,Owen (2006). Handbook of Pharmaceutical Excipients.
  31. C Raymond,Siân C Rowa,Owen (2006). Handbook of Pharmaceutical Excipients.
  32. N Unlu,Ludwig (1992). A comparative rheological study on carbopol viscous solutions and evaluation of their suitability as the ophthalmic vehicle and artificial tears.
  33. Vianna Lopez (2010). A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery.
  34. G Barretta,S Nazzi (2011). Synergistic interaction between TS-polysaccharide and hyaluronic acid: implications in the formulations of eye drops.
  35. Koraygum Sibelbozdag (2008). Formulation and Invitro evaluation of cysteamine hydrochloride viscous solution for treatment of corneal cystinosis.
  36. V Jack (2005). Pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
  37. D Attwood (2001). In-situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride.
  38. Indu Kaur,Manjit Singh,Meenakshi Kanwar (2000). Formulation and evaluation of ophthalmic preparations of acetazolamide.
  39. O Felt (1999). Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention.
  40. Forming Jingcai (2004). J&J patents foaming oil preparation.
  41. Jeffrey Hutterer (2005). Figure 3.22 - Share of countries in ICT-related patents filed under the PCT, 2005.
  42. John Denick,Zhenze Hu (1998). US profile for propylene glycol.
  43. Farnes (2009). Ketorolac tromethamine compositions for treating ocular pain.
  44. Orest Olejnik,Fred Wendel (1997). Ophthalmic formulation.
  45. Krisriino Kyyronen,Arrourrri (1990). Improved ocular: systemic absorption ratio of timolol by viscous vehicle and phenylephrine.
  46. Koraygum Sibelbozdag (2008). Formulation and Invitro evaluation of cysteamine hydrochloride viscous solution for treatment of corneal cystinosis.
  47. P Patel,D Shastri (2011). Formulation and evaluation of pH triggered acyclovir ophthalmic In-situ gel.
  48. S Kulkarni,H Sandeep (2010). Effect of a single drop of latanoprost ophthalmic gel on intra ocular pressure in the treatment of glaucoma.
  49. O Hussein,H Salama (2009). Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride.
  50. Koraygumu Sibelbozdag (2008). Formulation and Invitro evaluation of cysteamine hydrochloride viscous solution for treatment of corneal cystinosis.
  51. Matthias,Sigrid (1999). Polyacrylic acid/ polyvinylpyrrolidone bipolymeric systems.i. Rheological and mucoadhesive properties of formulations potentially useful for the treatment of dry-eye-syndrome.
  52. P Jansook,E Stefánsson (2010). Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension.
  53. Sunisha Kulkarni,Surya Gupta,Neeraj Upmanyu,S Tonpay (2011). Solubility Enhancement of Water Insoluble Drug for Ophthalmic Formulation..
  54. Chrystèle Le Bourlais,Liliane Acar,Hosein Zia,Pierre Sado,Thomas Needham,Roger Leverge (1998). Ophthalmic drug delivery systems—Recent advances.
  55. M Zignani,C Tabatabay,R Gurny (1995). Topical semi-solid drug delivery: kinetics and tolerance of ophthalmic hydrogels.
  56. G Colo,Y Zambito (2009). Selected polysaccharide at comparison for their mucoadhesiveness and effect on precorneal resident of different drugs in rabbit model.
  57. L Mayol,F Quaglia (2008). A novel poloxamers/ hyaluronic acid in situ forming hydrogel for drug delivery: rheological, mucoadhesive and in vitro release properties.
  58. R Masteikova,Z Chalupova (2003). Stimuli-sensitive hydrogels in controlled and sustained drug delivery.
  59. G Shetty,R Charyulu (2013). A study on stability and in-vivo drug release of naphazoline and antazoline in situ gelling systems for ocular delivery.
Show All References
Download References

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

M. B. Vyas B. Vyas. . "Formulation & Evaluation of Eye Care Solution of Vasoconstrictor and Antihistaminic Drug for Conjuctivitis". Global Journal of Medical Research, Global Journal of Medical Research - B: Pharma, Drug Discovery, Toxicology & Medicine GJMR-B Volume 15 (GJMR Volume 15 Issue B2).

More Citation Formats

Download Citation

  • Open Access
  • CC-BY-ND-NC 4.0
Download Article
Access OJS
Journal Specifications

Crossref Journal DOI 10.17406/gjmr

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Not Found
Classification
GJMR-B Classification NLMC Code: QV 701
  • Published June 10, 2015
Version of record

v1.2

Issue date
June 10, 2015

Language
English
Order Article Reprint
Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

View in VR
Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

View in 3D
Article Matrices
Total Views: 279K
Total Downloads: 678
All Trends

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Formulation & Evaluation of Eye Care Solution of Vasoconstrictor and Antihistaminic Drug for Conjuctivitis

M. B. Vyas Vyas
M. B. Vyas Vyas Sardar Patel University
  • Published June 10, 2015